Symphytum Officinale Whole

Dosage for Symphytum Officinale Whole is highly individualized and must be determined by a specialist based on the patient's sensitivity levels. There is no 'standard' dose for non-standardized extracts.

Diagnostic Dosing

For skin prick testing, a single drop of the 1:20 w/v or 1:10 w/v extract is applied to the skin (usually the forearm or back), followed by a sterile lancet prick. A positive control (histamine) and a negative control (saline) are used simultaneously for comparison.

Immunotherapy Dosing

Immunotherapy follows two phases:

1. 1Build-up Phase: Starting with a very low dose (often 0.05 mL of a 1:100,000 dilution), injections are given 1–3 times per week. The dose is gradually increased until the 'maintenance dose' is reached.
2. 2Maintenance Phase: Once the maintenance dose is reached (typically 0.5 mL of a 1:10 or 1:20 concentration), injections are spaced out to every 2–4 weeks for a period of 3–5 years.

Symphytum Officinale Whole is not generally recommended for children under the age of 5 due to the difficulty of communicating symptoms of systemic reactions. In older children, dosing is similar to adult dosing but must be approached with extreme caution, starting at even lower dilutions to minimize the risk of anaphylaxis.

Renal Impairment

No specific dosage adjustments are provided for renal impairment; however, patients with compromised renal function should be monitored for their ability to clear the metabolic byproducts of the extract.

Hepatic Impairment

Contraindication Alert: Due to the known hepatotoxic potential of pyrrolizidine alkaloids found in Symphytum species, use of this extract in patients with pre-existing hepatic impairment or liver disease is generally avoided. If used, frequent Liver Function Tests (LFTs) are mandatory.

Elderly Patients

Elderly patients may have reduced physiological reserve to handle a systemic allergic reaction. Dosing should be conservative, and the patient's cardiovascular status must be evaluated before starting immunotherapy.

This medication is never for self-administration. It must be administered by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment (including epinephrine).

• Administration: Subcutaneous injection (for immunotherapy) should be given in the outer aspect of the upper arm.
• Observation: Patients must remain in the clinic for at least 30 minutes following any injection to monitor for signs of anaphylaxis.
• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose in the immunotherapy schedule is missed, the next dose may need to be reduced depending on how much time has elapsed.

• 1-2 weeks late: Repeat the last dose.
• 3-4 weeks late: Reduce the dose by one or two increments.
• Over 4 weeks late: The build-up phase may need to be restarted at a much lower concentration.

An overdose of Symphytum Officinale Whole typically manifests as an immediate systemic allergic reaction. Symptoms include generalized urticaria (hives), angioedema (swelling), bronchospasm, and hypotension (low blood pressure).

Emergency Measures:

1. 1Immediate administration of Epinephrine (1:1000) intramuscularly.
2. 2Maintenance of airway and administration of oxygen.
3. 3Intravenous fluids for hypotension.
4. 4Administration of antihistamines and corticosteroids as secondary treatments.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to adjust your dose or administration schedule without medical guidance.

Most patients undergoing treatment or testing with Symphytum Officinale Whole will experience localized reactions. These are generally considered a normal part of the immune response to the extract.

• Local Wheal and Flare: A raised, itchy bump at the test site, similar to a mosquito bite. This typically peaks within 15–20 minutes and resolves within a few hours.
• Injection Site Redness: Sustained redness at the site of immunotherapy injections that may last 24–48 hours.
• Local Pruritus (Itching): Intense itching at the site of administration.

• Large Local Reactions (LLR): Swelling at the injection site that exceeds 5-10 cm in diameter. This may be accompanied by warmth and discomfort.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy session.
• Headache: Mild to moderate tension-type headaches.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Rhinitis: Sneezing, runny nose, or nasal congestion triggered by the systemic presence of the allergen.
• Gastrointestinal Distress: Nausea or abdominal cramping, which can be an early sign of a systemic reaction.

> Warning: Stop the procedure and call for emergency help immediately if you experience any of the following symptoms of anaphylaxis.

• Anaphylactic Shock: A sudden drop in blood pressure, rapid or weak pulse, and fainting.
• Laryngeal Edema: Swelling of the throat that makes it difficult to breathe or swallow.
• Wheezing or Severe Bronchospasm: Difficulty breathing or a whistling sound when exhaling.
• Angioedema: Swelling of the lips, tongue, or face.
• Cyanosis: A bluish tint to the skin or nails, indicating a lack of oxygen.

Because Symphytum Officinale contains pyrrolizidine alkaloids (PAs), there is a theoretical risk associated with long-term, high-dose exposure, even if administered subcutaneously.

• Hepatotoxicity: Chronic exposure to PAs can lead to Hepatic Veno-Occlusive Disease (VOD), also known as Sinusoidal Obstruction Syndrome. This involves the blockage of small veins in the liver, leading to cirrhosis and liver failure.
• Carcinogenicity: In animal studies, long-term exposure to Comfrey has been linked to the development of liver tumors. While the risk from small-volume allergenic extracts is considered low, it cannot be entirely ruled out.

While non-standardized plant extracts often do not carry a specific branded Black Box Warning, the FDA requires a general warning for all allergenic extracts regarding the risk of Severe Systemic Allergic Reactions.

Summary of Warning:

Symphytum Officinale Whole can cause severe, life-threatening systemic reactions, including anaphylaxis. It should only be administered by healthcare professionals prepared to manage such reactions. Patients with unstable asthma are at increased risk for fatal reactions. Always observe the patient for at least 30 minutes post-injection.

Report any unusual symptoms, particularly changes in liver function (jaundice, dark urine) or respiratory status, to your healthcare provider immediately.

Symphytum Officinale Whole is a potent biological substance. It is intended only for use by clinicians specializing in allergy and immunology. Patients must be informed that while the goal of treatment is to reduce allergy symptoms, the treatment itself carries an inherent risk of triggering the very symptoms it aims to treat.

No specific product-specific FDA black box warning exists for the 'Symphytum Officinale Whole' extract specifically, but it falls under the class-wide warning for Allergenic Extracts: "This product can cause severe systemic reactions, including anaphylaxis, which may be fatal. Patients must be observed for at least 30 minutes in a facility equipped to treat such reactions."

• Anaphylaxis Risk: The primary risk is a systemic Type I hypersensitivity reaction. Risk factors include high sensitivity levels, the use of beta-blockers, and poorly controlled asthma.
• Hepatotoxicity (Liver Toxicity): Symphytum species are known to contain pyrrolizidine alkaloids. Internal use is banned in many countries. While the amount in an allergenic extract is small, systemic absorption over years of immunotherapy warrants caution.
• Asthma Stability: Patients experiencing an asthma exacerbation should not receive immunotherapy injections until their symptoms are stable and their Peak Expiratory Flow (PEF) has returned to baseline.
• Infection: Injections should be deferred if the patient has an acute infection or fever, as this may increase the risk of a systemic reaction.

• Liver Function Tests (LFTs): Baseline and periodic LFTs (ALT, AST, Bilirubin) are recommended for patients undergoing long-term immunotherapy with Symphytum-derived products to monitor for PA-induced hepatotoxicity.
• Pulmonary Function: For asthmatic patients, FEV1 or PEF should be checked before each injection.
• Visual Inspection: The injection site must be inspected for large local reactions before the patient leaves the clinic.

Generally, this extract does not interfere with the ability to drive. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until cleared by a physician.

Alcohol consumption should be avoided on the day of an immunotherapy injection. Alcohol can cause vasodilation, which may increase the rate of allergen absorption from the injection site and potentially mask early signs of an allergic reaction.

If a patient experiences a severe systemic reaction, the clinician must re-evaluate the risk-benefit ratio of continuing immunotherapy. If discontinued, no tapering is required as there is no physiological dependence; however, the patient's allergy symptoms will likely return to baseline levels over time.

> Important: Discuss all your medical conditions, especially liver disease and asthma, with your healthcare provider before starting Symphytum Officinale Whole.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are contraindicated in patients receiving allergenic extracts. Beta-blockers can increase the severity of anaphylaxis and, more importantly, make the reaction refractory (resistant) to treatment with epinephrine.
• Internal Comfrey Supplements: Patients should never take oral Comfrey supplements while receiving Symphytum extracts, as this significantly increases the cumulative dose of toxic pyrrolizidine alkaloids.

• ACE Inhibitors (e.g., Lisinopril): May increase the risk of systemic reactions or worsen the hypotension associated with anaphylaxis.
• MAO Inhibitors (e.g., Phenelzine): Can interfere with the metabolism of epinephrine if it needs to be administered for an allergic reaction.
• Tricyclic Antidepressants (e.g., Amitriptyline): May potentiate the effects of epinephrine, leading to severe hypertension or arrhythmias if an emergency occurs.

• Antihistamines (e.g., Loratadine, Cetirizine): These must be discontinued at least 3–7 days prior to skin testing, as they will suppress the wheal and flare response, leading to a false-negative result.
• H2 Blockers (e.g., Famotidine): May also partially suppress skin test results.
• Systemic Corticosteroids: Long-term use of high-dose steroids may dampen the immune response to immunotherapy, potentially reducing its efficacy.

• Cross-Reactive Foods: Patients allergic to Comfrey may show cross-reactivity with other members of the Boraginaceae family or certain pollens (e.g., Ragweed). Consuming these foods shortly before an injection may increase the 'allergic load' and risk of reaction.
• High-Fat Meals: No direct interaction, but heavy meals may complicate the management of gastrointestinal symptoms during a systemic reaction.

• Hepatotoxic Herbs: Avoid other herbs known to stress the liver, such as Kava Kava, Pennyroyal, or high doses of Green Tea Extract, as these may synergize with the pyrrolizidine alkaloids in Symphytum to cause liver damage.
• St. John's Wort: May induce CYP3A4, which is involved in the metabolic activation of pyrrolizidine alkaloids into their toxic pyrrole forms.

• Liver Function Tests: Symphytum exposure may lead to elevations in ALT, AST, and alkaline phosphatase.
• Skin Tests: The presence of the extract in the system does not typically interfere with other lab tests, but it will obviously cause a positive result on a specific IgE (RAST) test.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or depression.

• Severe/Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted values are at an unacceptably high risk for fatal bronchospasm during immunotherapy.
• Pre-existing Liver Disease: Including cirrhosis, hepatitis, or portal hypertension. The presence of pyrrolizidine alkaloids in Symphytum Officinale Whole makes it dangerous for individuals with compromised hepatic function due to the risk of Veno-Occlusive Disease (VOD).
• History of Severe Anaphylaxis to Comfrey: If a patient has previously had a life-threatening reaction to very small amounts of the plant or extract, the risk of immunotherapy may outweigh the benefits.
• Beta-Blocker Therapy: Due to the inability to effectively treat anaphylaxis with epinephrine.

• Pregnancy: While not an absolute contraindication for continuing maintenance therapy, starting new immunotherapy during pregnancy is generally avoided due to the risk of fetal hypoxia during a systemic reaction.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may experience a flare of their condition when the immune system is stimulated by allergenic extracts.
• Malignancy: Immunotherapy is generally avoided in patients with active cancer, as the effects on the immune system are not fully understood in this context.

Patients with known hypersensitivity to other members of the Boraginaceae family (such as Borage, Heliotrope, or Forget-me-not) may exhibit cross-sensitivity to Symphytum Officinale Whole. Clinicians should perform cautious testing if these sensitivities are suspected.

> Important: Your healthcare provider will evaluate your complete medical history, including your respiratory and hepatic health, before prescribing Symphytum Officinale Whole.

Pregnancy Category C. There are no adequate and well-controlled studies of Symphytum Officinale Whole in pregnant women. The primary concern is not direct teratogenicity of the proteins, but the risk of maternal anaphylaxis. Anaphylaxis can lead to maternal hypotension and uterine hypoperfusion, resulting in fetal hypoxia, neurological damage, or fetal death. Furthermore, the pyrrolizidine alkaloids in Comfrey are known to cross the placental barrier and are hepatotoxic to the fetus. Initiation of immunotherapy is not recommended during pregnancy.

It is not known whether the components of Symphytum Officinale Whole are excreted in human milk. However, pyrrolizidine alkaloids are known to pass into breast milk and can pose a significant risk of liver damage to the nursing infant. Caution should be exercised, and a risk-benefit analysis must be conducted. In many cases, breastfeeding is discouraged if the mother is receiving significant doses of Comfrey-derived products.

Safety and effectiveness in children under the age of 5 have not been established. In older children, immunotherapy is generally effective but requires close monitoring. Children may not be able to articulate early symptoms of a systemic reaction (e.g., itchy palms, 'feeling of doom'), making administration more hazardous.

Clinical studies of allergenic extracts did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. Geriatric patients often have co-morbidities such as cardiovascular disease or COPD that make them poorer candidates for handling the stress of a systemic allergic reaction. Renal and hepatic function should be assessed before treatment.

While the proteins in the extract are not primarily cleared by the kidneys in their intact form, the metabolic byproducts are. There is no specific GFR-based dosing, but patients with Stage 4 or 5 Chronic Kidney Disease (CKD) should be monitored closely for systemic toxicity.

Use with extreme caution or avoid. Symphytum Officinale is inherently hepatotoxic. In patients with Child-Pugh Class B or C impairment, the use of this extract is generally contraindicated due to the risk of exacerbating liver failure or triggering Veno-Occlusive Disease.

> Important: Special populations require individualized medical assessment and often more frequent monitoring of liver and lung function.

Symphytum Officinale Whole acts as an immunomodulator. In the diagnostic phase, it utilizes the 'effector' arm of the immune system (mast cell degranulation) to signal sensitivity. In the therapeutic phase, it induces 'immunological tolerance.' This involves the induction of Regulatory T cells (Tregs) which secrete IL-10 and TGF-beta. These cytokines suppress Th2 responses and induce B cells to switch from IgE production to IgG4 production. IgG4 acts as a 'blocking antibody,' preventing the allergen from reaching the IgE on mast cells.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations produce larger wheals. In immunotherapy, higher maintenance doses are generally more effective but carry a higher risk of systemic reactions.
• Onset: Diagnostic results are seen in 15–20 minutes. The therapeutic onset of immunotherapy is slow, often taking 6–12 months to show significant symptom reduction.
• Duration: The effects of a successful 3–5 year course of immunotherapy can last for several years after discontinuation.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous/Local) |

| Protein Binding | Variable (Allergen-specific) |

| Half-life | 2–6 hours (Proteins) |

| Tmax | 15–30 minutes (Local) |

| Metabolism | Proteolysis / Hepatic (PAs) |

| Excretion | Renal (Metabolites) |

• Composition: A complex mixture of proteins, glycoproteins, polysaccharides, and alkaloids.
• Key Constituents: Allantoin (promotes cell proliferation), Pyrrolizidine Alkaloids (e.g., symphytine, echimidine), and Rosmarinic acid.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various allergenic proteins.

Symphytum Officinale Whole belongs to the class of Non-Standardized Plant Allergenic Extracts. It is grouped with other botanical extracts like Ragweed, Oak, and Grass extracts used in clinical allergy practice.